MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertaso, F.
Right arrow Articles by Dolphin, A. C.

Vol. 63, Issue 4, 832-843, April 2003

Mechanism of Action of Gq to Inhibit Gbeta gamma Modulation of CaV2.2 Calcium Channels: Probed by the Use of Receptor-Galpha Tandems

Federica Bertaso, Richard J. Ward, Patricia Viard, Graeme Milligan, and Annette C. Dolphin

Department of Pharmacology, University College London, London, United Kingdom (F.B., P.V., A.C.D.); and Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom (R.J.W., G.M.)

The stable interaction of a G-protein coupled receptor and a particular partner G-protein was made possible by creating tandems between the alpha 2A adrenergic receptor (alpha 2A-R) and pertussis toxin-resistant mutants of different Galpha subunits of heterotrimeric G-proteins. Both alpha 2A-R-Galpha o and alpha 2A-R-Galpha i proved able to reconstitute agonist-induced voltage-dependent inhibition of N-type calcium channels (CaV2.2) similar to the wild-type alpha 2A-R when expressed in COS-7 cells. The interaction of Gq with the Gi/o signaling pathways was studied by expressing either Galpha q or a chimeric construct based on Galpha q containing the last five amino acids of Galpha z, which is activated by alpha 2A-R. It was found that Galpha qz5 activated by the wild-type alpha 2A-R inhibited CaV2.2 currents in a voltage-independent fashion. Furthermore, Galpha qz5 counteracted the voltage-dependent inhibition resulting from alpha 2A-R-Galpha o activation. We subsequently investigated the basis for the behavior of Galpha qz5. Our evidence suggests that this occurs as a result of a downstream effect of activation of Galpha qz5 because it was blocked by C-terminal construct of phospholipase Cbeta 1. Furthermore it is likely to occur in part via protein kinase C (PKC) activation, because the PKC activator phorbol dibutyrate mimicked the effects of Galpha qz5 in alpha 2A-R-Galpha o-transfected cells. Conversely, cells expressing both alpha 2A-R-Galpha o and Galpha qz5 exhibited a partial restoration of voltage-dependent inhibition in the presence of the PKC inhibitor bisindolylmaleimide I (GF 109203X). The potential sites of phosphorylation are discussed.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
S. Dai, D. D. Hall, and J. W. Hell
Supramolecular Assemblies and Localized Regulation of Voltage-Gated Ion Channels
Physiol Rev, April 1, 2009; 89(2): 411 - 452.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
H. W. Tedford and G. W. Zamponi
Direct G Protein Modulation of Cav2 Calcium Channels
Pharmacol. Rev., December 1, 2006; 58(4): 837 - 862.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. C. Dolphin
G Protein Modulation of Voltage-Gated Calcium Channels
Pharmacol. Rev., December 1, 2003; 55(4): 607 - 627.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics